ASH 2023 | The impact of blast enumeration & co-occurring myelodysplasia-related mutations in NPM1-mutated AML
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the impact of blast enumeration and co-occurring myelodysplasia related mutations in NPM1-mutated acute myeloid leukemia (AML). Blast enumeration had little impact on disease prognosis, whereas co-occurrence of myelodysplasia related mutations was associated with worse outcomes, which were more profound in younger patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: QualWorld, Gerson Lehrman Group, Abbvie, Blueprint Medicine, Caris Diagnostics, Guidepoint, Recordati/ EUSA Pharma, Daiichi Sankyo
Research Funding: Astellas, Amgen
Current equity holder in publicly-traded company: Abbvie
